SAGE Therapeutics (SAGE) Receives a Hold from Raymond James


In a report released today, Danielle Brill from Raymond James reiterated a Hold rating on SAGE Therapeutics (SAGE). The company’s shares closed last Tuesday at $71.14.

According to TipRanks.com, Brill is a 4-star analyst with an average return of 13.8% and a 49.3% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $103.43 average price target, implying a 34.3% upside from current levels. In a report issued on April 19, Morgan Stanley also maintained a Hold rating on the stock with a $81.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $98.39 and a one-year low of $33.82. Currently, SAGE Therapeutics has an average volume of 463.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts